Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of oral KVD900 for on-demand treatment of hereditary angioedema attacks
MOH_2022-08-14_011979Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (3 arms), sponsored by KalVista Pharmaceuticals. Started Jul 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on MOH_2022-08-14_011979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-14_011979.